VDF Inaugurates National Corporate Advisory Board

The Vascular Disease Foundation is pleased to announce plans to initiate a National Corporate Advisory Board. The goal of this new board is to reduce the mortality and devastating effects from vascular disease, by providing support, participating in an annual roundtable discussion on vascular health initiatives and help keep vascular health concerns high on the national agenda.

Inaugural members of the new National Corporate Advisory Board include Diomed Holdings, Inc., developer and marketer of the proprietary Endovenous Laser Treatment (EVLT®) for varicose veins, and AstraZeneca, LP a leading pharmaceutical company. Additionally, Diomed will sponsor a portion of the Foundation's website dedicated to venous disease. More than 25 million Americans are affected by some form of venous disease. AstraZeneca is a sponsor of the Foundation's newsletter, Keeeping In Circulation, and provided a grant used for a new educational brochure on venous thromboembolism.

"We are delighted that Diomed and AstraZeneca have made significant commitments to the Vascular Disease Foundation's future," said Peter Gloviczki, M.D., President of VDF's board of directors. We anticipate five or six inaugural members joining this new board before its first meeting in late October.